Graft-Vs-Host Disease

Latest News


Study Hall

Study Hall powered by, Oncology Nursing News is a dedicated hub designed for Advanced Practice Providers, offering an easy-to-navigate platform to support your clinical practice. Explore a comprehensive collection of articles, videos and learning modules.

Study Hall

CME Content


The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to abatacept (Orencia) to prevent moderate or severe acute graft-versus-host disease (GvHD) in patients who underwent a hematopoietic stem cell transplant and are not related to their donors, according to Bristol-Myers Squibb, the manufacturer of the drug.